Mydecine Innovations Group announced that it is sponsoring a study titled: The neurocognitive effects of low dose psychoactive substances,µ at Australia·s Macquarie University. The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fel ow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people who already have an established practice of microdosing will come to the lab to complete a cutting-edge battery of measures. The study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing. Microdosing has a strong following of self-administering users, but actual medical data is currently thin. By applying scientific rigor like this, along with the ongoing work at the Imperial College London, the company helping to build a library of solid data sets that begin to tell how microdosing works, and how it can be used in future clinical trials for various mental health issues.